Horny Goat Weed: Icariin, Sexual-Health Claims and Safety

What is horny goat weed?

Horny goat weed is a common name for several Epimedium species used in traditional Chinese herbal medicine. Supplements usually contain leaf material or extracts and may be standardized to icariin, one of their flavonoids.

People buy it mainly for libido and erections, with additional claims for fatigue and bone health. The human research includes specific flavonoid mixtures, standardized extracts and products containing several ingredients; these preparations answer different questions.

Historical uses and modern preparations

Memorial Sloan Kettering describes^[1] Epimedium's traditional Chinese-medicine uses for fatigue, sexual problems, arthritic pain and nerve pain. Sexual-use preparations have included herbal formulas. This institutional account documents the uses; it does not establish a single historical species, recipe or dose for today's products.

Why do people take horny goat weed?

Common dosage

As of 2026, there is no recognized recommended daily amount for horny goat weed. The clinical sources reviewed here do not establish a reliable general dose for libido or erectile symptoms. The amounts used in bone and blood-level studies describe those experiments, rather than a sexual-health regimen.

What should the label disclose?

Check the Epimedium species, leaf or other plant part, actual extract amount and any icariin specification. In a blend, find the amount of every active ingredient rather than relying on the formula's total weight.

An icariin percentage describes composition. It cannot tell you whether the product improves erections, and a trial of a multi-ingredient formula cannot identify how much benefit came from its Epimedium ingredient.

Products promising immediate drug-like effects deserve particular scrutiny. FDA notifications^[2] document hidden ingredients in sexual-enhancement products. Check the exact product name, but absence from this incomplete list is not a safety clearance.

Drawbacks and side effects

MSK advises caution^[1] for hormone-sensitive cancer and cardiovascular disease. Its medicine-interaction summary also flags drugs processed by the CYP3A4 enzyme, while stating that clinical relevance is unknown. The case reports cannot tell us how often serious reactions occur. Pregnancy and breastfeeding lack adequate safety evidence for self-directed concentrated use.

What do the bone studies show?

A defined mixture and bone density over two years

The 2007 randomized trial^[3] enrolled 100 women who were 10–18 years past natural menopause and had low lumbar-spine bone density. Half received 60 mg icariin, 15 mg daidzein and 3 mg genistein daily; half received placebo. Both groups also received 300 mg elemental calcium daily. Eighty-five women completed 24 months.

At two years, average lumbar-spine density changed by +1.3% with the mixture versus −2.4% with placebo. At the femoral neck, the part of the thigh bone near the hip, changes were +1.6% versus −1.8%. Both between-group comparisons favored the mixture. The increases within the mixture group alone were not statistically significant, so preservation relative to the placebo group's losses is the useful interpretation. At 12 months, the spine comparison favored the mixture, while the hip comparison remained uncertain.

This was a three-flavonoid preparation with calcium, not an icariin-only or ordinary leaf-capsule trial. Bone density was the measured outcome; the abstract does not establish fewer fractures. Other Epimedium formulas have also been studied against osteoporosis medicines, but their ingredients and overlapping trial results need further assessment before a broader conclusion is possible.

A shorter study measured blood markers

A 2021 trial^[4] randomized 58 healthy postmenopausal women to 740 mg/day of an Epimedium prenylflavonoid extract or placebo for six weeks; all completed the study. Prenylflavonoids are a group of plant compounds that includes icariin. The principal study questions concerned safety and what compounds reached the blood.

At eight weeks after starting, two weeks after the capsules stopped, bone-specific alkaline phosphatase—a marker associated with bone formation—was higher with the extract. The abstract gives a statistical result but no size for that difference. A comparison of TRAF6, a protein involved in bone-resorbing cell signaling, was inconclusive. These marker findings do not establish a change in bone density or a reduction in fractures.

The abstract reported no significant adverse symptoms or changes in the liver, kidney and blood measures checked during this short study. That observation applies to this extract and follow-up period.

Does horny goat weed relieve fatigue?

A 2021 preliminary study^[5] tested Epimedium extract in ten men with Gulf War Illness, a chronic illness involving several symptoms. Each man took placebo for 30 days, then a lower extract dose for 30 days and a higher dose for another 30 days. The methods specify a 20% icariin extract at 500 and 1,000 mg/day, but the discussion gives twice those amounts; the report leaves the exact regimen inconsistent.

Neither active period improved overall illness severity beyond placebo. Secondary fatigue and pain ratings also showed no significant advantage over placebo. Some ratings improved from the initial baseline, but placebo did too.

This was a small screening study with the same placebo-to-low-to-high sequence for everyone. Some participants had previously tested other botanicals in the same research program, so lingering effects could influence later periods. Its results concern these men and this illness, rather than every cause of tiredness.

Does icariin work like an erection medicine?

Icariin can inhibit phosphodiesterase-5, an enzyme involved in erection signaling, in laboratory experiments. In the 2008 enzyme study^[6], the compound with potency close to sildenafil was a chemically modified icariin derivative. Unmodified icariin was substantially weaker. The experiment tested enzyme activity, not erections in men taking an oral supplement.

Human blood-level studies add another distinction. In a randomized placebo-controlled study of 30 healthy men^[7], single doses of standardized extract were 370, 740 or 1,110 mg; icariin itself was below the test's detection level, while metabolites—related compounds formed as the ingredients are processed in the body—were detected. The six-week study in postmenopausal women also found these related compounds while icariin itself was below detection. This does not mean nothing was absorbed. It means the compounds measured in circulation differed from the original ingredient highlighted on the label.

What about products that combine several ingredients?

The Cappra crossover trial^[8] involved 63 Thai men with mild or mild-to-moderate erectile dysfunction; 61 completed it. Cappra was a 13-component formula containing Epimedium. Men took one tablet about an hour before sexual activity, at least three times during each two-week treatment period, with a one-week washout before switching between the product and placebo.

The erectile-function part of the International Index of Erectile Function, a questionnaire about sexual function, improved by an average 4.87 points with Cappra versus 3.44 with placebo. That comparison was statistically significant. These average scores alone do not show how noticeable the extra 1.43 points would be. The other four questionnaire domains—orgasm, desire, intercourse satisfaction and overall satisfaction—did not differ significantly. The study tested the full formula; it cannot isolate Epimedium's contribution.

The bottom line

Horny goat weed's human research is more varied than its sexual-performance marketing suggests. One defined flavonoid mixture produced favorable bone-density comparisons in postmenopausal women, while a short extract trial found a bone-marker signal and a small Gulf War Illness study found no fatigue advantage over placebo. Reliable single-herb sexual benefits and a general effective dose remain unestablished.

Help us improve this article

Spotted an error or found a source we should consider? Tell us which part of this article needs another look and include a link if you have one. Please leave out personal health details and lab results; we can’t answer individual medical questions.

Your name

Email address

What would you like to share?Select a topicCorrectionSource or research suggestionArticle requestAccessibility issueBusiness inquirySomething else

Your message

Continue to email →Email us directly